Mark H Katz1, Michael W Lee, Mantu Gupta. 1. Department of Urology, New York Presbyterian Hospital, Columbia University Medical Center, New York, New York, USA.
Abstract
BACKGROUND AND PURPOSE: We report our office-based technique and results of BCG and interferon-alpha2B (BCG-IFN) for upper-tract transitional-cell carcinoma (TCC). TECHNIQUE: Papillary lesions were ablated endoscopically after biopsy. Office flexible cystoscopy was performed, and a 0.038-inch guidewire or Glidewire was advanced into the renal pelvis. A 5F ureteral catheter was placed over the wire, and a free flow of urine was confirmed. Half-strength BCG + 50 million units of IFN was infused under low pressure for 1 hour. The ureteral catheter was removed, and patients were instructed to void 1 hour later. RESULTS: Between 2000 and 2006, 10 patients with a median age of 72 years were treated with BCG-IFN for upper-tract TCC in 11 renal units. Follow-up ureteroscopy with or without biopsy was performed after a 6-week induction to evaluate response. Complete responders were placed on a maintenance regimen. With a median follow-up of 24 months, 8 patients (80%) demonstrated a complete response (CR) to therapy, and 2 had a partial response (decrease in tumor size, number, or both). Six patients with a CR have continued on maintenance therapy. There were no side effects or complications with the instillation therapy. CONCLUSION: We describe a safe, minimally invasive, and effective office-based technique for upper-tract BCG-IFN instillation.
BACKGROUND AND PURPOSE: We report our office-based technique and results of BCG and interferon-alpha2B (BCG-IFN) for upper-tract transitional-cell carcinoma (TCC). TECHNIQUE: Papillary lesions were ablated endoscopically after biopsy. Office flexible cystoscopy was performed, and a 0.038-inch guidewire or Glidewire was advanced into the renal pelvis. A 5F ureteral catheter was placed over the wire, and a free flow of urine was confirmed. Half-strength BCG + 50 million units of IFN was infused under low pressure for 1 hour. The ureteral catheter was removed, and patients were instructed to void 1 hour later. RESULTS: Between 2000 and 2006, 10 patients with a median age of 72 years were treated with BCG-IFN for upper-tract TCC in 11 renal units. Follow-up ureteroscopy with or without biopsy was performed after a 6-week induction to evaluate response. Complete responders were placed on a maintenance regimen. With a median follow-up of 24 months, 8 patients (80%) demonstrated a complete response (CR) to therapy, and 2 had a partial response (decrease in tumor size, number, or both). Six patients with a CR have continued on maintenance therapy. There were no side effects or complications with the instillation therapy. CONCLUSION: We describe a safe, minimally invasive, and effective office-based technique for upper-tract BCG-IFN instillation.
Authors: Michael Metcalfe; Gavin Wagenheim; Lianchun Xiao; John Papadopoulos; Neema Navai; John W Davis; Jose A Karam; Ashish M Kamat; Christopher G Wood; Colin P Dinney; Surena F Matin Journal: J Endourol Date: 2017-07-21 Impact factor: 2.942
Authors: Barak Rosenzweig; Renato B Corradi; Sadna Budhu; Ricardo Alvim; Pedro Recabal; Stephen La Rosa; Alex Somma; Sebastien Monette; Avigdor Scherz; Kwanghee Kim; Jonathan A Coleman Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379